Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2001 Nov;8(6):1282-5.
doi: 10.1128/CDLI.8.6.1282-1285.2001.

Efficacy of a less-sensitive enzyme immunoassay (3A11-LS) for early diagnosis of human immunodeficiency virus Type 1 infection in infants

Affiliations
Comparative Study

Efficacy of a less-sensitive enzyme immunoassay (3A11-LS) for early diagnosis of human immunodeficiency virus Type 1 infection in infants

D Candal et al. Clin Diagn Lab Immunol. 2001 Nov.

Abstract

We evaluated a less-sensitive enzyme immunoassay (3A11-LS) for its possible use for early diagnosis of human immunodeficiency virus type 1 (HIV-1) infection in infants. The results were compared with those from the immunoglobulin G-capture enzyme immunoassay. A total of 239 sera from 77 infants were tested. All 25 sera from the 10 infants born to seronegative mothers were found to be negative by both assays. Forty-one seroreverting infants showed a complete decay of maternal antibodies by 4 months by the 3A11-LS assay. However, the assay detected HIV antibodies in only 9 (36%) of 25 sera collected from infected infants between 4 and 6 months and in 27 (63%) of 43 sera collected after 6 months of age. Further analysis with alternative cutoff values indicated that the 3A11-LS had a sensitivity of 12 to 44% and a specificity of 90 to 100% for infants between 4-6 months of age. This data suggest that a diagnosis of HIV infection in some of the infants could be made after 4 months of age by the 3A11-LS assay, although a negative 3A11-LS test result may not rule out infection and may require a further followup.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
HIV-1 antibody detected in seroreverting infants (A, upper panels) or in HIV-1-infected infants (B, lower panels) with respect to their ages. SOD values obtained by the 3A11-LS assay (●, left panels) or OD values by IgG-CEIA (○, right panels) are shown.

Similar articles

References

    1. Abrams E J, Matheson P, Thomas P, Thea D M, Krasinski K, Lambert G, Shaffer N, Bamji M, Hutson D, Grimm K. Neonatal predictors of infection status and early death among 332 infants at risk of HIV-1 infection monitored prospectively from birth. Pediatrics. 1995;96:451–458. - PubMed
    1. Amadori A, DeRossi A, Chieco-Bianchi L, Giaquitto C, De Maria A, Ades A E. Diagnosis of human immunodeficiency virus 1 infection in infants: in vitro production of virus-specific antibody in lymphocytes. Pediatr Infect Dis J. 1990;9:26–30. - PubMed
    1. Bulterys M, Fowler M G. Prevention of HIV infection in children. Pediatr Clin North Am. 2000;47:241–260. - PubMed
    1. Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, Leroy V, Simonon A, Cartoux M, Combe P, Ouangré A, Ramon R, Ky-Zerbo O, Montcho C, Salamon R, Rouzioux C, Van de Perre P, Mandelbrot L. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso : a double blind placebo-controlled multicentre trial. Lancet. 1999;353:786–792. - PubMed
    1. DeCock K M, Fowler M G, Mercier E, Vincenzi I, Saba J, Hoff E, Alnwick D J, Rogers M, Shaffer N. Prevention of mother-to-child HIV transmission in resource-poor settings: translating research into policy and practice. JAMA. 2000;283:1175–1182. - PubMed

Publication types